Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series Authors: Eleonora Gugole, Edoardo Tamellini, Sara Jance, Nicola Serafin, Pietro Antonini, Chiara Colato, Mauro Krampera, Isacco Ferrarini, Ilaria Tanasi Published: 2026 ABSTRACT AbstractMyelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML) are increasingly recognized to exhibit immune dysregulation, which can occasionally present with autoinflammatory manifestations. We describe four patients with MDS/AML harboring p53 mutations and a complex karyotype who developed inflammatory serositis without infectious correlation. All patients showed clinical improvement following corticosteroid therapy.Keywords: Serositis, MDS/AML, TP53 mutation, Complex karyotype, Steroid therapy Introduction Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies characterized by cytopenias in one or more lineages and a variable risk of progression to Acute Myeloid Leukemia (AML). MDS may be associated with a broad spectrum of immune-mediated manifestations, ranging from asymptomatic serological abnormalities to classic connective tissue disorders, such as rheumatoid arthritis, relapsing polychondritis, systemic lupus erythematosus, and mixed connective tissue disease [1]. Approximately 10–14% of MDS cases are associated with systemic inflammatory or autoinflammatory manifestations (SIAMs) [2]. Among these, systemic vasculitis, persistent fever, and serositis are the most frequently reported. Emerging evidence suggests that MDS harboring a complex karyotype and TP53 mutations may be associated with autoinflammatory serositis, such as pleuro-pericardial effusion; however, clinical reports focusing on this specific subset remain scarce in the current literature. Here, we report four patients diagnosed with MDS or AML—according to the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) criteria [3, 4]—with complex karyotypes and TP53 mutations, who developed inflammatory manifestations in the absence of an identifiable infectious etiology. Case #1 In March 2023, a 50-year-old male was diagnosed with TP53-mutated AML, therapy-related (according to ICC 2022). The patient’s oncological history was significant for T-cell lymphoma, treated in January 2012 with 12 cycles of VACOP-B, and Hodgkin disease, treated in October 2012 with two cycles of DHAOx followed by autologous stem cell transplantation (ASCT). At the time of AML diagnosis, bone marrow evaluation revealed 12% blast infiltration with a phenotype CD117+, CD13+, CD 34+/-, CD38+, CD45+/-, HLA-DR +, CD33+, CD123+/-. Molecular and cytogenetic analyses identified a TP53 mutation [c.528 C > G p.(Cys176Trp), VAF 87%] and a complex karyotype[46 ~ 47,XY, t(5;6)(q13?;q22?),+21[cp10]46,XY [1]. Upon hospitalisation for induction therapy, the patient presented with fever and respiratory distress requiring oxygen supplementation. Radiographic imaging documented massive bilateral pleural (Fig. 1) and pericardial effusions. Although empiric antibiotic therapy was initiated, no clinical improvement was observed. Extensive diagnostic workup, including repeated blood cultures and microbiological/cytological examinations of the pleural fluid, was negative for infectious agents. Flow cytometry of the pleural fluid identified a small fraction of leukemic blasts. Suspecting autoinflammatory serositis, the patient was started on low-dose corticosteroid therapy, which led to significant clinical and radiographic improvement, subsequently allowing for the initiation of induction chemotherapy with CPX-351. Notably, attempts to taper the corticosteroid dose resulted in a recurrence of symptomatic pleural effusion, necessitating a dose increase. The disease proved refractory to induction therapy, and second-line treatment with decitabine plus venetoclax was initiated. Throughout the clinical course, low-dose corticosteroids remained essential for controlling the inflammatory manifestations. Unfortunately, the patient died due to disease progression while awaiting an HLA-identical donor for hematopoietic stem cell transplantation. Chest X-ray findings of the reported cases. (A–D) Posteroanterior radiographs of Case #1 (A), Case #2 (B), Case #3 (C), and Case #4 (D). All images demonstrate the presence of pleural effusion, while no focal pulmonary lesions or parenchymal consolidations are observed Case #2 In March 2025, a 64-year-old male with no significant prior medical history was diagnosed with TP-53 mutated AML (according to ICC 2022). Bone marrow evaluation at diagnosis showed 20% blast infiltration with the following phenotype CD117+, CD13++, CD34+/-, CD38+, HLA-DR ++, CD33+/-, CD123+. Cytogenetic and molecular profiling revealed a TP53 mutation [exon 8, c.824G > A, p.(Cys275Tyr), VAF 75.4%] and a complex karyotype: [47,XY, add(3)(p12),t(4;17)(q22;q22),der(5)t(5;12)(q13;q21),+8,del(12)(q23),add(20)(q11.2). FISH: der(17)t(4;17)(TP53-),der(5)t(5;12)(EGR1-,RPS14-),add(20)(PTPRT-,MYBL2-)]. The patient initially presented with fever, mild dyspnea, and chest pain. Radiographic imaging documented pericarditis and mild pleural effusion (Fig. 1). Despite the initiation of empiric antibiotic therapy, the patient’s clinical condition rapidly deteriorated, progressing to acute respiratory failure with increasing pleural effusion that necessitated non-invasive ventilation (NIV). Although chest X-rays showed pulmonary consolidation, extensive microbiological workup—including repeated blood and urine cultures, bronchoalveolar lavage (BAL), and multiplex PCR (FilmArray) on respiratory secretions—consistently yielded negative results. The clinical course was further complicated by acute kidney injury (AKI) of unknown etiology, requiring hemodialysis after pre-renal, post-renal, and iatrogenic causes were excluded. Following a transient stabilization of respiratory status, the patient began the first cycle of azacitidine. However, before completion of the cycle, he experienced progressive clinical deterioration and ultimately died due to multi-organ failure (MOF). Case #3 In April 2025, a 62-year-old male with no significant prior medical history was diagnosed with TP53-mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML according to ICC 2022). Bone marrow evaluation revealed 15% blast infiltration. Flow cytometric analysis showed the presence of a CD34 + population accounting for 7% of nucleated cells, Molecular and cytogenetic profiling identified a TP53 mutation [exon 5, c.396 C > G, p.(Lys132Asn), VAF 95%] and a complex karyotype [[45,XY,2,add(5)(q31),der(6)(t(2;6)(q31;p23),del(7)(q22),del(12)(p11.2p13),del(20)(q11.2q13.1)[19]/46,XY [3]. The patient initially presented with fever and a significant elevation in inflammatory markers, with no response to broad-spectrum antibiotic therapy. Microbiological screenings of blood and urine samples were consistently negative. Subsequently, the patient became symptomatic for epigastric pain and dyspnea: radiographic imaging documented pericarditis and pleural effusion (Fig. 1). Thoracentesis was performed: microbiological, cytological, and flow cytometric analyses of the pleural fluid were unremarkable, but consequently, the patient developed a thoracic hematoma necessitating drainage via exploratory thoracotomy. During the procedure, a lung biopsy was obtained. Histological analysis revealed acute fibrinous and organizing pneumonia (AFOP) with sterile neutrophilic infiltrates, interpreted as a manifestation of an MDS-related autoinflammatory process (Fig. 2). Lung parenchyma showing fibrino-hemorragic pleuritis with sterile suppurative inflammation (arrow) (x2, Hematoxylin- Eosin). Inset: proliferative phase of AFOP showing intra-alveolar fibrin in the form of “fibrin balls” lacking neutrophils, and mildly widened interstitial septa with cattered lymphocytes (x20, Hematoxylin-Eosin) Based on the histological findings, the patient started low-dose corticosteroid therapy, resulting in progressive clinical and radiological improvement, as well as normalization of inflammatory markers. Induction therapy with azacitidine plus venetoclax was subsequently initiated. However, continuous low-dose steroid therapy was required throughout the treatment course to manage recurrent autoinflammatory manifestations. At the most recent follow-up, the patient remains alive; however, bone marrow assessment after the fourth cycle showed disease progression (20% blasts). The patient is currently receiving supportive and palliative care. Case #4 In August 2025, a 55-year-old female was diagnosed with TP53-mutated AML, therapy-related (according to ICC 2022). Her medical history was significant for a BRCA2-associated mammary tumor diagnosed in 2016, treated with four cycles of EC90 chemotherapy, followed by 12 doses of paclitaxel and surgery. After documenting pulmonary and cerebral metastases in 2018 and a relapse in 2019, she underwent further radiotherapy, surgery, and chemotherapy, concluding treatment in 2024 with confirmed complete remission. At AML diagnosis, bone marrow evaluation showed 20% blast infiltration (CD34+, CD117+, CD13+, HLA-DR ++, CD33+, CD 45+/-). Molecular and cytogenetic profiling identified two TP53 mutations [exon 6, c.646G > T, p.(Val216Leu), VAF 61%; and exon 4, c.356 C > G, p.(Ala119Gly), VAF 3.2%] and a complex karyotype [[43,XX,3,der(5;17)(p10;q10),7,del(12)(p11.2)[23]/46,XX [2]. FISH: der(5;17)(D5S721/D5S23+,EGR1-)[12]]. During hospitalization for AML, the patient developed fever and respiratory distress requiring oxygen supplementation. Laboratory analysis revealed significantly elevated inflammatory markers. Although empiric antibiotic therapy was initiated, no clinical improvement was observed. Chest X-ray and CT imaging documented pleural effusion (Fig. 1). Extensive microbiological workup, including blood cultures and a multiplex pneumonia panel on a BAL specimen, yielded negative results. Given the persistent fever and rising inflammatory markers despite antibiotics, autoinflammatory serositis was suspected. Initiation of low-dose corticosteroid therapy led to rapid resolution of fever and decreased inflammatory markers. Subsequently, the patient began induction therapy with azacitidine plus venetoclax alongside a gradual steroid taper. Following four cycles of treatment, the patient achieved complete remission (CR) and is currently awaiting hematopoietic stem cell transplantation from an HLA-identical donor. Patients’clinical course is resumed in Table 1. Table 1Summary of patient’s characteristics and clinical coursePatientSexAgeICC 2022 diagnosisCytogenetic and molecular featuresInitial presentationMicrobiological workupKey inflammatory manifestationsSteroid responseClinical outcome#1M51TP53-mutated AML,therapy-relatedTP53 mut (VAF 87%); complex karyotypeFever, dyspnea (March 2023)Negative (Blood, pleural fluid)Massive pleuropericardial effusionRapid improvement; recurrence upon taperingDead (disease progression)#2M65TP53-mutated AMLTP53 mut (VAF 75.4%); complex karyotypeFever, chest pain (March 2025)Negative (Blood, urine, BAL/FilmArray)Pericarditis, pleural effusion, AKINot administered (Rapid decline)Dead (MOF)#3M62TP53-mutated MDS/AMLTP53 mut (VAF 95%); complex karyotypeFever, epigastric pain (April 2025)Negative (Blood, Urine, Pleural fluid)Pericarditis, pleural effusion, AFOP (Histology)Significant improvement; required for maintenanceAlive in active disease#4F56TP53-mutated AML, therapy-relatedTP53 mut (VAF 61%); complex karyotypeFever, respiratory distress (August 2025)Negative (Blood, BAL/FilmArray)Pleural effusionRapid resolution of fever and markersAlive in complete remissionAML Acute myeloid leukemia, MDS Myelodysplastic syndrome, VAF Variant allele frequency, BAL Bronchoalveolar lavage, AKI Acute kidney injury, AFOP Acute fibrinous and organizing pneumonia, MOF Multiorgan failure Summary of patient’s characteristics and clinical course TP53-mutated AML, therapy-related AML Acute myeloid leukemia, MDS Myelodysplastic syndrome, VAF Variant allele frequency, BAL Bronchoalveolar lavage, AKI Acute kidney injury, AFOP Acute fibrinous and organizing pneumonia, MOF Multiorgan failure Discussion and conclusion The association between MDS and systemic inflammatory/autoimmune manifestations (SIAMs) is increasingly recognized, with VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) currently representing the prototype of hematoinflammatory diseases [5]. In our series, none of the patients met the clinical or molecular criteria for VEXAS, except for the patient in Cas #3, whose UBA1 mutation test was negative. While autoimmune manifestations in MDS are well-documented, specific associations with molecular pathogenesis remain poorly defined. The literature reports sporadic cases of serositis, such as pericardial effusion [6] or autoimmune hemolytic anemia [7], which typically respond favorably to corticosteroid treatment. In refractory cases, other immunosuppressants (e.g., azathioprine, cyclophosphamide) or immunomodulating agents have been employed. The underlying pathophysiology of SIAMs in MDS involves a complex immune dysregulation. In vitro studies have demonstrated an aberrant cytokine profile (including interleukins α or β, IL-6, IL-8), and dysfunctional CD8 T-cells and NK cells, which contribute to an inflammatory bone marrow microenvironment [8]. Notably, the role of the monocyte-macrophage lineage appears central in this context. As reviewed by Ma et al., monocytes and macrophages are key drivers of autoimmune diseases through their plasticity and ability to secrete pro-inflammatory mediators [9]. In the setting of TP53-mutated myeloid malignancies, the loss of TP53 regulatory function may further exacerbate this myeloid-driven inflammation, as TP53 is known to modulate innate immune responses and macrophage polarization. In our series, all four patients harbored TP53 mutations and complex karyotypes. Despite a relatively low blast count in some cases, these patients developed severe autoinflammatory manifestations that responded to corticosteroid therapy (mainly prednisone). These observations support the hypothesis of a possible association between molecular and cytogenetic findings and certain rare clinical manifestations, identifying a subpopulation that may benefit from steroid therapy from the onset of typical clinical manifestations and could promptly initiate disease-specific treatment. Our case series highlights a potential association between specific cytogenetic/molecular alterations (complex karyotype and TP53 mutations) and rare autoinflammatory manifestations in MDS/AML. Recognizing this subset of patients is clinically crucial, as early initiation of steroid therapy can stabilize the patient, allowing for the timely start of disease-specific treatments. Further in vitro and in vivo studies are warranted to clarify the molecular crosstalk between TP53 deficiency and the hyper-inflammatory state of the myeloid compartment. Authors’ contributions E.G. wrote the manuscript; S.J. and N.S contributed to the drafting of the case reports; C.C. and P.A. provided the figure and the related caption; I.T. and I.F. were responsible for the treatment of the patients, contributed to the conceptualization of the manuscript, reviewed and edited the manuscript; E.T. and M.K. reviewed and edited the manuscript. All authors read, revised and approved the submitted version of the manuscript. Funding The authors have not received any funding during the creation of this manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki. Consent for publication Written informed consent was obtained from the patients involved in the study or from patient’s next of kin. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.